The Journal of Thoracic and Cardiovascular Surgery
Volume 138, Issue 4 , Pages 897-903, October 2009

A comparison before and after aprotinin was suspended in cardiac surgery: Different results in the real world from a single cardiac center in China

  • Xianqiang Wang, MD

      Affiliations

    • Department of Cardiovascular Surgery and Research Center for Cardiovascular Regenerative Medicine, Beijing, China
    • X.W. and Z.Z contributed equally to this article.
  • ,
  • Zhe Zheng, MD

      Affiliations

    • Department of Cardiovascular Surgery and Research Center for Cardiovascular Regenerative Medicine, Beijing, China
    • X.W. and Z.Z contributed equally to this article.
  • ,
  • Hushan Ao, MD

      Affiliations

    • Department of Anesthesia, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • ,
  • Shiju Zhang, MD

      Affiliations

    • Department of Cardiovascular Surgery and Research Center for Cardiovascular Regenerative Medicine, Beijing, China
  • ,
  • Yang Wang, MD

      Affiliations

    • Department of Cardiovascular Surgery and Research Center for Cardiovascular Regenerative Medicine, Beijing, China
  • ,
  • Hao Zhang, MD

      Affiliations

    • Department of Cardiovascular Surgery and Research Center for Cardiovascular Regenerative Medicine, Beijing, China
  • ,
  • Lihuan Li, MD

      Affiliations

    • Department of Anesthesia, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • ,
  • Shengshou Hu, MD

      Affiliations

    • Department of Cardiovascular Surgery and Research Center for Cardiovascular Regenerative Medicine, Beijing, China
    • Corresponding Author InformationAddress for reprints: Shengshou Hu, MD, Chief, Department of Surgery; Director, Research Center for Cardiovascular Regenerative Medicine, Cardiovascular Institute and Fuwai Hospital; Chinese Academy of Medical Science and Peking Union Medical College, 167A Beilishi Road, Xi Cheng District, Beijing 100037, People's Republic of China.

Received 4 December 2008; received in revised form 18 February 2009; accepted 9 March 2009. published online 22 May 2009.

Objective

Use of aprotinin has been suspended in cardiac surgery since recent studies reported its risks associated with mortality and other adverse events. This study was to investigate the safety and efficacy of aprotinin through a comparison before and after aprotinin was suspended in cardiac surgery.

Methods

We designed a case–control study in two groups of patients who underwent cardiac surgery just before and after aprotinin was suspended in China. The aprotinin group (n = 1699) was defined as operations performed from June 19, 2007, to December 18, 2007, when aprotinin was used in all the patients. The control group (n = 2225) was defined as operations performed from December 19, 2007, to June 18, 2008, when aprotinin was not used. We compared early postoperative outcomes between the two groups.

Results

The aprotinin group had less postoperative blood loss, transfusion requirement, and reoperation for bleeding. Application of aprotinin did not increase the risk of in-hospital mortality (0.5% vs 1.0%; P = .08) and other major adverse outcome events, including renal, cardiac, neurologic, and pulmonary complications. The aprotinin group had a shorter mechanical ventilation time (P = .04), a lower rate of delayed mechanical ventilation time (P = .04), and a higher arterial oxygen tension/inspired oxygen fraction ratio in arterial blood gas analysis (P < .001). Multivariable logistic regression analysis confirmed findings from univariate analysis. After propensity adjustment for the baseline characteristics, we obtained similar results.

Conclusions

Use of aprotinin in cardiac surgery could reduce blood loss and transfusion requirement significantly and showed a protective effect on the lungs, but it did not increase the risk of mortality or major complications.

Abbreviations and Acronyms: BART, Blood Conservation Using Antifibrinolytics in a Randomized Trial, CABG, coronary artery bypass grafting, CI, confidence intervals, CPB, cardiopulmonary bypass, ICU, intensive care unit, KIU, kallikrein international units, PaO2/FIO2, arterial oxygen tension/inspired oxygen fraction ratio

CTSNet classification: 1, 16, 18

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The study was funded by Key Projects in the National Science & Technology Pillar Program during the Eleventh Five-year Plan Period (2006BAI01A09) and Key Projects of Beijing Municipal Science & Technology Commission (D0906004040391).

PII: S0022-5223(09)00415-2

doi:10.1016/j.jtcvs.2009.03.021

The Journal of Thoracic and Cardiovascular Surgery
Volume 138, Issue 4 , Pages 897-903, October 2009